Abstract 127
| Time point | No paclitaxel | 0.2 μg/mm2 | 0.7 μg/mm2 | 1.4 μg/mm2 | 2.7 μg/mm2 |
|---|---|---|---|---|---|
| TLR, target lesion revascularisation. | |||||
| Clinical outcome data for 2-year follow-up in the ELUTES trial. No significant differences in clinical outcome were detected between the paclitaxel stents at any dose and the bare metal stent using a two-tailed Fisher test. | |||||
| 0–6 months | |||||
| n | 38 | 37 | 39 | 39 | 37 |
| Death | 0 | 0 | 0 | 0 | 1 |
| CABG | 0 | 0 | 0 | 0 | 0 |
| Q-wave MI | 0 | 0 | 0 | 0 | 0 |
| Non-Q MI | 0 | 0 | 1 | 0 | 1 |
| SAT | 1 | 0 | 0 | 0 | 1 |
| TLR (PCI) | 4 | 1 | 0 | 3 | 1 |
| 6–12 months | |||||
| n | 37 | 35 | 39 | 38 | 37 |
| Death or MI | 0 | 0 | 0 | 0 | 0 |
| CABG | 1 | 0 | 0 | 0 | 0 |
| TLR (PCI) | 1 | 2 | 2 | 1 | 1 |
| 12–24 months | |||||
| n | 32 | 28 | 33 | 30 | 29 |
| Death or MI | 0 | 0 | 0 | 0 | 0 |
| CABG | 0 | 0 | 0 | 0 | 1 |
| TLR (PCI) | 0 | 0 | 1 | 0 | 0 |
| Event-free survival at 24 months | 25/32 (78%) | 25/28 (89%) | 28/33 (85%) | 26/30 (87%) | 23/29 (79%) |